-
Meta, US states agree $16.7 bn settlement in landmark teen safety case
-
CIA director was on 'semi-routine' mission in Moscow: Trump
-
'Point of no return' if Israel-Hamas truce fails: US envoy to Gaza board
-
Aldeguer switches to Rossi's VR46 for next season
-
Barcelona holding out hope for Alvarez as Atletico resist sale
-
Rent TRON Energy and Reduce USDT Fees : TronBid Expands Marketplace
-
Werro basks in new status, shelves world record talk
-
Pakistan captain Babar Azam returns against England '90 percent fit'
-
Bill Gates warns world unprepared for AI upheaval
-
Stocks mixed as oil drops, inflation stays high
-
Prince Harry and family arrive back in Britain: UK media
-
Improving standards transform pole vault as spectacle, says Duplantis
-
German plan for sugar tax on Coke Zero fizzles out
-
India close in on win despite Sri Lanka fightback in second Test
-
Deadly flood hits Nepal-Tibet border, hundreds unaccounted for
-
MEXC TradFi Gala Concludes With Over 170,000 Registrations and $4.3 Billion in Daily Trading Volume
-
Tongue says Root has left England in no doubt over conduct standards
-
Olympic skating champion Liu to skip new season
-
Flags lowered across US for country music legend Dolly Parton
-
Benfica sign midfielder Palhinha from Bayern
-
Stocks gain as oil drops on Mideast hopes
-
Flick says Barca may go without striker as Atletico resist Alvarez sale
-
Bouaddi joins Man City for Premier League teenage record £85.6 mn
-
Too hot to incubate: Nile crocodiles hatch on their own in French reserve
-
Reclusive Hungarian author Peter Nadas dies aged 83
-
Spurs closing in on Man City's Marmoush after signing Savio
-
Man City sign Lille's Bouaddi for 100 mn euros
-
Celtic count the cost of Champions League flop
-
Sooriyabandara, Mendis lead Sri Lanka fightback after follow-on
-
Lebanon accuses Israel of burning forest, farmland in south
-
With ropes and chants, thousands move Japanese castle
-
Nepal floods at China border kill 8, cause 'major casualties' in Tibet
-
Zurich Diamond League: five events to watch
-
France eases cow diets as cheesemakers sweat
-
'Black smoke' chokes Pakistan maternity ward as hospital fire kills 14 infants
-
America unites in mourning for Dolly Parton
-
French flight attendant wins landmark breast cancer ruling
-
Meta and US states discuss settlement in landmark social media trial: report
-
Sri Lanka 83-2 after India enforce follow-on in second Test
-
Fire haze threatens health of millions in Indonesia, ministry warns
-
LIGHTWAIT Exhibition Explores Vulnerability and Connection in London
-
Pakistan hospital fire kills 14 infants
-
Senegal-made sickle cell treatment raises hopes, reduces costs
-
Iceland to vote on resuming EU talks in close referendum
-
Dolly Parton Dies at 80 After Brief Cancer Battle
-
Iran says Hormuz strait still closed despite transit corridor talks
-
North Korea to 'bring joy' to Kim with 100 athletes at Asian Games
-
'Our patron saint': Tennesseans mourn local hero Dolly Parton
-
US LGBTQ community mourns 'diva' Dolly Parton
-
Australian police hunt thieves in $250,000 oyster heist
New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning
NEW YORK, NY / ACCESS Newswire / March 25, 2026 / New to The Street, a premier financial media platform known for its national television distribution and integrated investor engagement strategy, today announced a strategic 12-part media partnership with IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company leveraging artificial intelligence to develop treatments for Alzheimer's disease and metabolic disorders.
The multi-faceted campaign is designed to elevate IGC Pharma's visibility across institutional and retail investor audiences through a coordinated media strategy that includes long-form television interviews, national TV commercial distribution, high-impact outdoor billboard placements, and curated accredited investor events in key financial markets.
Through this initiative, IGC Pharma will be featured across New to The Street's sponsored programming on Fox Business and Bloomberg Television, alongside amplification to a combined digital audience exceeding 4.45 million YouTube subscribers. The campaign will also include dominant outdoor placements in Times Square and the New York City Financial District, as well as earned media distribution across major U.S. broadcast affiliates.
"This partnership represents a strategic step forward in expanding our visibility within the global investment community," said Ram Mukunda, CEO of IGC Pharma. "New to The Street's unmatched ability to combine television, digital distribution, and outdoor media provides us with a powerful platform to communicate our clinical progress, including our Phase 2 CALMA trial, and to position IGC Pharma at the forefront of AI-driven biopharmaceutical innovation."
"We are proud to launch this 12-part series with IGC Pharma at a time when Alzheimer's continues to impact millions of families across the United States and around the world," said Vince Caruso, co-founder and CEO of New to The Street. "This is about more than visibility - it's about bringing forward companies that are working on real solutions. IGC Pharma is advancing meaningful progress in an area of critical need, and through our platform, we aim to elevate their story to the global investment community while offering a sense of hope and potential comfort to those affected by this devastating disease."
New to The Street's integrated platform is engineered to align media exposure with capital markets objectives - driving narrative control, investor engagement, and long-term brand equity for emerging and growth-stage public companies.
About New to The Street
New to The Street is one of the longest-running U.S. and international sponsored television brands, broadcasting weekly as sponsored programming on Fox Business and Bloomberg Television. The platform delivers long-form interviews with innovative public and private companies, combining national TV exposure with digital, social, and outdoor media amplification.
With over 4.45 million YouTube subscribers and one of the most comprehensive media distribution ecosystems in the financial space, New to The Street integrates television broadcasting, earned media placements across ABC, NBC, and CBS affiliates, and dominant billboard visibility throughout Times Square and the NYC Financial District. The platform also provides direct access to accredited investors through curated in-person and virtual events, creating a full-cycle investor awareness and engagement solution.
About IGC Pharma
IGC Pharma, Inc. (NYSE American:IGC) is a clinical-stage biotechnology company leveraging artificial intelligence to develop innovative treatments for Alzheimer's disease and metabolic disorders.
The Company's lead therapeutic candidate, IGC-AD1, is currently in a Phase 2 clinical trial (CALMA) targeting agitation in Alzheimer's dementia. Its pipeline also includes TGR-63, focused on amyloid plaque reduction, along with additional early-stage programs addressing neurodegeneration, tau pathology, and metabolic dysfunction.
By integrating AI into drug discovery, clinical trial design, and patient targeting, IGC Pharma is accelerating development timelines and advancing a portfolio of therapies aimed at addressing significant unmet medical needs. The Company maintains a robust patent portfolio supporting its innovation-driven approach.
Media Contact
Monica Brennan
New to The Street
[email protected]
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially. Investors are encouraged to review IGC Pharma's filings with the U.S. Securities and Exchange Commission for additional information regarding these risks.
SOURCE: New to The Street
View the original press release on ACCESS Newswire
E.Flores--AT